Inclusion Criteria:

          1. Participants with one of the following cancers:

               -  Pathologically confirmed, locally recurrent or metastatic solid tumors

               -  Histologically or cytologically confirmed NSCLC that is recurrent or metastatic

               -  Histologically or cytologically diagnosed advanced solid tumors with metastasis
                  in liver and/or lung

          2. Disease progression after SOC therapy or in the opinion of the Investigator unlikely
             to benefit from SOC therapy.

          3. Age 18 years or older.

          4. Measurable disease per RECIST version 1.1.

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.

          6. Life expectancy > 12 weeks.

          7. Demonstrate adequate organ function as defined by acceptable laboratory testing
             results.

          8. Women of child-bearing potential (WCBP) and men must agree to use adequate
             contraception prior to study entry, while on study treatment, and for six months after
             receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to
             C1D1.

          9. Last dose of previous anticancer therapy ≥ 21 days, radiotherapy > 21 days, or
             surgical intervention > 21 days prior to the first dose of T3011.

         10. Recovered from all prior anticancer therapy toxicities.

         11. Willingness to provide fresh tumor biopsy specimens as specified in the Schedule of
             Assessments.

         12. Capable of understanding and complying with protocol requirements.

         13. Signed and dated institutional review board/independent ethics committee (IRB/IEC)
             approved informed consent form (ICF) before any protocol-directed screening procedures
             are performed.

        Exclusion Criteria:

          1. Prior treatment with another oncolytic virus or cellular therapy.

          2. Previous unacceptable intolerance to anti-PD-1 monoclonal antibody.

          3. Requires continued concurrent systemic therapy with any drug active against HSV.

          4. Live vaccines within 4 weeks of initiation of study treatment.

          5. Primary or acquired immunodeficient states.

          6. Pregnant or lactating.

          7. Splenectomy, previous allogenic tissue/solid organ transplant.

          8. Active hepatitis B virus, hepatitis C virus, or a positive serological test at
             Screening.

          9. Active autoimmune disease or medical conditions requiring chronic steroid.

         10. Untreated and/or symptomatic metastatic central nervous system (CNS) disease.

         11. History of seizure disorders within 6 months of Screening.

         12. Active oral or skin herpes lesion at Screening.

         13. Congestive heart failure, active coronary artery disease, unevaluated new onset angina
             within 3 months or unstable angina, or clinically significant cardiac arrhythmias.

         14. History of allergic reactions attributed to compounds of similar biological
             composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or their excipients.

         15. Known or suspected active infection with SARS-CoV-2 virus.

         16. Other systemic conditions or organ abnormalities that, in the opinion of the
             Investigator, may interfere with the conduct and/or interpretation of the current
             study.